Brought to you by 
Schwarz Pharma, Discovery Therapeutics in Parkinson's deal
24 Aug 2005
Executive Summary
Schwarz Pharma AG's US affiliate Schwarz Pharma Inc. will complete development of Discovery Therapeutics Inc.'s Phase II transdermally delivered dopamine agonist N-0923 (later given the generic name rotigotine) for treating Parkinson's disease. Schwarz gets marketing rights worldwide except Japan.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Transdermal
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Schwarz Pharma, Discovery Therapeutics in Parkinson's deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice